Two pharmacutical companies combined resources in order to develop a vaccination against Herpes Virus
The Herpes type 2 morbidity rate for teens and young adults is tremendously high, however, if enough people take an active role in intervention and preventative treatment, the rate could drop significantly.
Yet, to date, there are no FDA approved vaccines against the genital herpes virus. Which is pretty absurd considering the fact that so many people are infected with herpes. To be more specific, about one out of every six people aged 14 to 49 years have genital herpes [1].
Development of a vaccine or specific drug is a very long and expensive process, which requires many approvals along the way in order to obtain the safest and most effective product.
As I grew up, I was always told that two is always better than one, and that’s true regarding all areas of life. So when two pharmaceutical companies decide to join forces in order to develop a vaccine for herpes, I understand can why, as well as praise their efforts to do so.
Both companies, pharmaceutical firm Sanofi Pasteur and biotech firm Immune Design chose to work together in order to develop an effective Herpes type 2 vaccine [2].
Both companies, pharmaceutical firm Sanofi Pasteur and biotech firm Immune Design chose to work together in order to develop an effective Herpes type 2 vaccine [2].
Although they both have vaccines in early testing , they still decided to combine their resources in order to be able to succeed where other companies have failed.
But wait, how shall we treat Herpes until a vaccine is developed? Here’s a thought- how about treatment based on natural ingredients?
It turns out that there are only two natural antiviral products which have been clinically proven effective: Novirin and Gene-Eden-VIR [3].
Apparently, Herpes virus can remain latent in the body, which is basically a “sleepy state”. In this state, the virus does not cause any health problems and the infected person doesn’t even know he is infected [4]!
The formula of these natural antiviral products was designed to help the immune system target the “sleepy” herpes.
Until a vaccine is developed, our main goal is to treat people who have been infected, and prevent disease transmission for people who have not yet been infected.
In order to do so, we must show responsibility by being aware to all current treatments on the market.
Reference:
1. CDC.com – Genital Herpes – CDC Fact Sheet. Last updated on July 1, 2014.
cdc.gov/std/herpes/stdfact-herpes.htm
2. Taylor, P. Sanofi to work with Immune Design on herpes vaccine. Published October 17, 2014. pmlive.com/pharma_news/sanofi_to_work_with_immune_design_on_herpes_vaccine_607263
3. Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013. scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-x7BeOSz90
4. Nahmias, André J., and William E. Josey. “Herpes simplex viruses 1 and 2.” Viral infections of humans. Springer US, 1984. 351-372.